Neuropathological findings from COVID-19 patients with neurological symptoms argue against a direct brain invasion of SARS-CoV-2: A critical systematic review.
COVID-19
SARS-CoV-2
brain
neurological symptoms
neuropathology
Journal
European journal of neurology
ISSN: 1468-1331
Titre abrégé: Eur J Neurol
Pays: England
ID NLM: 9506311
Informations de publication
Date de publication:
11 2021
11 2021
Historique:
received:
12
06
2021
accepted:
29
07
2021
pubmed:
3
8
2021
medline:
27
10
2021
entrez:
2
8
2021
Statut:
ppublish
Résumé
Neuropathological studies can elucidate the mechanisms of nervous system damage associated with SARS-CoV-2 infection. Despite literature on this topic is rapidly expanding, correlations between neurological symptoms and brain pathology findings in COVID-19 patients remain largely unknown. We performed a systematic literature review on neuropathological studies in COVID-19, including 438 patients from 45 articles published by April 22, 2021. We retrieved quantitative data regarding demographic, clinical, and neuropathological findings. We carried out a Wilcoxon rank sum test or χ Neuropathological findings in COVID-19 patients were microgliosis (52.5%), astrogliosis (45.6%), inflammatory infiltrates (44.0%), hypoxic-ischemic lesions (40.8%), edema (25.3%), and hemorrhagic lesions (20.5%). SARS-CoV-2 RNA and proteins were identified in brain specimens of 41.9% and 28.3% of subjects, respectively. Detailed clinical information was available from 245 patients (55.9%), and among them, 96 subjects (39.2%) had presented with neurological symptoms in association with typical COVID-19 manifestations. We found that: (i) the detection rate of SARS-CoV-2 RNA and proteins in brain specimens did not differ between patients with versus those without neurological symptoms; (ii) brain edema, hypoxic-ischemic lesions, and inflammatory infiltrates were more frequent in subjects with neurological impairment; (iii) neurological symptoms were more common among older individuals. Our systematic revision of clinical correlates in COVID-19 highlights the pathogenic relevance of brain inflammatory reaction and hypoxic-ischemic damage rather than neuronal viral load. This analysis indicates that a more focused study design is needed, especially in the perspective of potential therapeutic trials.
Sections du résumé
BACKGROUND AND PURPOSE
Neuropathological studies can elucidate the mechanisms of nervous system damage associated with SARS-CoV-2 infection. Despite literature on this topic is rapidly expanding, correlations between neurological symptoms and brain pathology findings in COVID-19 patients remain largely unknown.
METHODS
We performed a systematic literature review on neuropathological studies in COVID-19, including 438 patients from 45 articles published by April 22, 2021. We retrieved quantitative data regarding demographic, clinical, and neuropathological findings. We carried out a Wilcoxon rank sum test or χ
RESULTS
Neuropathological findings in COVID-19 patients were microgliosis (52.5%), astrogliosis (45.6%), inflammatory infiltrates (44.0%), hypoxic-ischemic lesions (40.8%), edema (25.3%), and hemorrhagic lesions (20.5%). SARS-CoV-2 RNA and proteins were identified in brain specimens of 41.9% and 28.3% of subjects, respectively. Detailed clinical information was available from 245 patients (55.9%), and among them, 96 subjects (39.2%) had presented with neurological symptoms in association with typical COVID-19 manifestations. We found that: (i) the detection rate of SARS-CoV-2 RNA and proteins in brain specimens did not differ between patients with versus those without neurological symptoms; (ii) brain edema, hypoxic-ischemic lesions, and inflammatory infiltrates were more frequent in subjects with neurological impairment; (iii) neurological symptoms were more common among older individuals.
CONCLUSIONS
Our systematic revision of clinical correlates in COVID-19 highlights the pathogenic relevance of brain inflammatory reaction and hypoxic-ischemic damage rather than neuronal viral load. This analysis indicates that a more focused study design is needed, especially in the perspective of potential therapeutic trials.
Identifiants
pubmed: 34339563
doi: 10.1111/ene.15045
pmc: PMC8444743
doi:
Substances chimiques
RNA, Viral
0
Types de publication
Journal Article
Review
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
3856-3865Informations de copyright
© 2021 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.
Références
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
JAMA. 2020 Apr 28;323(16):1574-1581
pubmed: 32250385
Respir Res. 2020 Sep 21;21(1):241
pubmed: 32957997
JAMA Neurol. 2021 Jun 1;78(6):760-762
pubmed: 33576767
New Microbes New Infect. 2020 Mar 27;35:100669
pubmed: 32322398
PLoS Pathog. 2020 Apr 28;16(4):e1008520
pubmed: 32343745
Nat Rev Neurosci. 2015 May;16(5):249-63
pubmed: 25891508
Syst Rev. 2015 Jan 01;4:1
pubmed: 25554246
PLoS One. 2020 Nov 17;15(11):e0241955
pubmed: 33201896
Lancet. 2020 May 9;395(10235):1517-1520
pubmed: 32311318
J Clin Neurosci. 2020 Nov;81:192-195
pubmed: 33222915
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
Eur J Neurol. 2021 Nov;28(11):3856-3865
pubmed: 34339563
Eur J Epidemiol. 2010 Sep;25(9):603-5
pubmed: 20652370
Lancet. 2020 May 2;395(10234):1417-1418
pubmed: 32325026
Med Klin Intensivmed Notfmed. 2020 Dec;115(Suppl 3):111-114
pubmed: 32291505
Lancet Neurol. 2021 Mar;20(3):169-170
pubmed: 33609467
J Neurol. 2020 Nov;267(11):3154-3156
pubmed: 32564153
Eur J Neurol. 2021 Oct;28(10):3360-3368
pubmed: 33884707
Clin Infect Dis. 2020 Nov 5;71(8):1937-1942
pubmed: 32301997
Thromb Res. 2019 Sep;181:77-83
pubmed: 31376606
N Engl J Med. 2020 Jun 11;382(24):2372-2374
pubmed: 32302078
Nat Commun. 2020 Oct 30;11(1):5493
pubmed: 33127906
Lancet Psychiatry. 2020 Oct;7(10):875-882
pubmed: 32593341
N Engl J Med. 2020 Jun 4;382(23):2268-2270
pubmed: 32294339
Front Neurol. 2021 Mar 12;12:643713
pubmed: 33776896
Radiol Case Rep. 2020 Jul 03;15(9):1705-1708
pubmed: 32733625
Int J Infect Dis. 2020 May;94:55-58
pubmed: 32251791
BMJ Evid Based Med. 2018 Apr;23(2):60-63
pubmed: 29420178
Lancet Neurol. 2020 Nov;19(11):919-929
pubmed: 33031735
Nature. 2020 Dec;588(7837):315-320
pubmed: 32846427
Lancet Microbe. 2020 Nov;1(7):e290-e299
pubmed: 33015653
N Engl J Med. 2020 Sep 3;383(10):989-992
pubmed: 32530583
J Neurol Neurosurg Psychiatry. 2021 Jul;92(7):751-756
pubmed: 33158914
Brain. 2021 Oct 22;144(9):2696-2708
pubmed: 33856027
Acta Neuropathol Commun. 2020 Aug 26;8(1):147
pubmed: 32847628
Curr Treat Options Neurol. 2020;22(11):40
pubmed: 33046957
Front Med (Lausanne). 2021 Jan 27;8:608215
pubmed: 33585523
Brain Behav Immun. 2020 Jul;87:149
pubmed: 32387508
Nat Rev Neurosci. 2014 Apr;15(4):209-16
pubmed: 24646669
EBioMedicine. 2020 May;55:102763
pubmed: 32361250
Acta Neuropathol. 2020 Oct;140(4):583-586
pubmed: 32851506
Eur J Neurol. 2020 Sep;27(9):1764-1773
pubmed: 32333487
Int J Hematol. 2021 Jan;113(1):45-57
pubmed: 33161508
Biol Sex Differ. 2020 May 25;11(1):29
pubmed: 32450906
Nat Neurosci. 2021 Mar;24(3):368-378
pubmed: 33328624
Infection. 2021 Feb;49(1):15-28
pubmed: 32860214
Cardiovasc Res. 2020 Aug 1;116(10):1666-1687
pubmed: 32352535